ATI Physical Therapy (ATIP) Q3 2024 earnings summary

Executive summary

• Net revenue grew 7.1% year-over-year to $190 million in Q3 2024, driven by higher patient visits and increased clinician headcount.

• Adjusted EBITDA rose to $12.1 million (6.4% margin), up from $9.4 million (5.3% margin) in Q3 2023.

• Net loss widened to $32.9 million from $14.6 million in Q3 2023, with net loss available to common stockholders at $40.8 million.

• Patient referrals and visits per day increased, with clinics seeing 1,400 more daily visits year-over-year.

• Liquidity remains a concern, with $23.5 million in cash and a need for additional capital by early 2025.

Financial highlights

• Net patient revenue increased 7.7% to $174.7 million; other revenue was flat at $15.3 million.

• Adjusted EBITDA for Q3 2024 was $12.1 million; net loss was $32.9 million.

• Salaries and related costs increased 8.7% to $106 million, driven by higher headcount and wage inflation.

• Cash used year-to-date was $13 million, a significant improvement from $63 million last year.

• Cash and cash equivalents at September 30, 2024, were $23.5 million; no available capacity under revolving credit facility.

Outlook and guidance

• Q4 2024 net revenue expected between $182 million and $192 million; Adjusted EBITDA guidance is $9 million to $14 million.

• Guidance reflects ongoing wage inflation and one less business day in Q4 compared to last year.

• Company expects to need additional liquidity by early 2025 to fund working capital, capital expenditures, and interest payments.